Sanofi Q4 revenue rises on Dupixent, but vaccine sales fall; a humble look at Dupixent

Exterior view of the Sanofi headquarters building

Editorial HJBC/iStock via Getty Images

Sanofi (NASDAQ: SNY) shares fell premarket on Friday after fourth-quarter sales rose on the back of the blockbuster drug Dupixent, but the well-known vaccine business fell.

He also secured the French pharmaceutical giant

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *